Clinical Cell Culture and Visiomed Group Ltd have received court approval for their planned merger.
The Federal Court in Perth gave its final approval on Tuesday to the schemes of arrangement between the two companies.
C3 Chief Executive Officer Andrew Cannon said the merger will place the new company in a strong position for growth.
"As a merged entity, we are now a more financially robust medical device group with a stronger balance sheet, better cashflows and an outstanding line of products," he said.
Visiomed and Clinical Cell Culture are merging under a scrip deal, with Visiomed shareholders receiving five Clinical Cell Culture shares for every seven Visiomed shares held.
VSG Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
